Ultragenyx Pharmaceutical | RARE - Interest Expense On Debt


Ultragenyx Pharmaceutical reported $19M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Esperion Therapeutics USD 22.64M 585K Dec/2025
Immunic 400K 400K Dec/2024
Insmed USD 20.6M 217K Dec/2025
Ionis Pharmaceuticals USD 18M 0 Dec/2025
Karyopharm Therapeutics USD 11.38M 2.43M Sep/2024
Kyowa Hakko Kirin JPY 435M 94M Dec/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Moderna USD 12.14B 12.13B Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xoma USD 3.4M 150K Jun/2024